In a move that speaks directly to the clash between federal edicts and the care for a vulnerable population, UCHealth and Denver Health have been compelled to suspend gender-affirming surgeries for transgender youth under the age of 19. This decision arrives on the heels of an executive order from President Donald Trump, which slashes federal support for such procedures, designating them as "chemical and surgical mutilation of children." As reported by 9News, the executive order was signed last Tuesday, forcing these healthcare institutions to carefully weigh the risk of losing critical funding against the needs of their patients.
Denver Health, in particular, is in a precarious position. As detailed by both 9News and The Denver Gazette, the hospital receives approximately $89 million annually from the federal government, a sum that doesn't even include additional Medicaid funding. Losing this financing is not something the hospital can feasibly endure, especially after leaders campaigned to convince Denver voters to pass a sales tax increase last November, aimed at pulling the institution out of its financial "death spiral."
Caught in this controversial policy shift are the transgender individuals who now face an abrupt halt to treatments that many consider life-saving. Saoirse Maloney, a transgender individual currently receiving care at Denver Health, as obtained by 9News, "I just see this raising the suicidality rate of trans kids and also trans adults, like, the 18-year-olds are adults," adding, "What's crazy to me is that they're being told that they can fight and die for this country, but they can't actually pursue things that they have the legal right to."
Denver Health did clarify, however, that behavioral counseling and transgender voice therapy would not be affected by the order. Meanwhile, concerns about mental health repercussions loom large in the shadow of the executive order. Advocates argue that the abrupt cessation of gender-affirming care could lead to a spike in significant mental health issues among young transgender populations, according to Evrim Ağacı, which highlighted the safety record of treatments like puberty blockers when used appropriately.
